Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of New Formulation SHR-1316 in Subjects With Advanced Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Wen Jing
- Phone Number: 17721286191
- Email: wen.jing@hengrui.com
Study Contact Backup
- Name: Yuya Wang
- Phone Number: 13918749176
- Email: yuya.wang@hengrui.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years.
- Histologically or cytologically confirmed advanced cancer in patients who are fail to current standard therapy or lack of effective therapy.
- Estimated life expectancy ≥12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ functions.
- If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment dose.
- Patients must be willing and able to provide written informed consent prior to the performance of any study-specific procedure.
Exclusion Criteria:
- Known history of hypersensitivity to any components of the SHR-1316 product.
Patient- Prior treatment with the following agents:
- "Check-point inhibitors", including Programmed death receptor-1 (PD-1), PD-L1;
- Receipt of investigational agents within 4 weeks prior to study treatment;
- Current treatment on another therapeutic clinical trial, unless the observational (non-interventional) clinical trials or follow-up of interventional clinical trials;
- Any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, target therapy, biotherapy or tumor embolization), administered within 4 weeks prior to study treatment; or within 6 weeks in the case of certain therapies (e.g., mitomycin C and nitrosoureas). Any such, unless discussed and explained with the sponsor;
- Anticipated need for any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, or biotherapy) during SHR-1316 treatment; except palliative radiotherapy;
- Receipt of any anti-cancer vaccines; receipt of immunomodulatory drugs within 4 weeks prior to study treatment; topical, nasal spray and inhaled corticosteroids as well as systemic steroid therapy in physiological doses (such as: prednisone ≤10 mg/day) are acceptable.
- Patients have unrecovered (ie, to NCI CTCAE grade ≤1) from all toxicity associated with previous treatments (exception: patients may enter with continuing alopecia irrespective of CTCAE grade; grade 2 peripheral nerve diseases).
- Known Active central nervous system (CNS) metastases; Patients who had previously received brain or meningeal metastasis therapy, who were clinically stable for at least 8 weeks, and who had stopped systemic sex hormone therapy (such as: prednisone > 10 mg/day) for more than 4 weeks were included.
- Subjects with active autoimmune disease, history of autoimmune diseases, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.
- Active or history of immune deficiency, such as human immunodeficiency virus (HIV) infection; History of organ transplantation.
- History or evidence of cardiovascular (CV) risk including any of the following: Congestive heart failure (Class >2) as defined by the New York Heart Association functional classification system (NYHA), unstable angina pectoris, Recent (within the past 12 months) history of myocardial infarction, clinically significant supraventricular or ventricular arrhythmias need treatment or intervention.
- Patients with clinically significant ECG abnormalities (QT interval corrected for rate by Fridericia's formula [QTcF] >470 msec for female and >450 msec for male on the ECG obtained at Screening).
- Active infection that need drug intervention or an unexplained fever >38.5°C (fever caused by cancer can be included according to the judgement of the researcher).
- Active pulmonary tuberculosis infection.
- Positive for Hepatitis B or C.
- Known history of psychoactive drug abuse, alcohol abuse or drug use.
- Known history of any other malignant cancer within past 3 years. Exceptions: completely resected basal cell carcinoma and squamous cell carcinoma of the skin; and completely resected carcinoma in situ of cervix.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment group
|
SHR-1316 administrated intravenously (IV) at protocol defined dose levels
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The incidence and severity of adverse events/serious adverse events (based on NCI-CTC AE 5.0)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
Maximum plasma concentration (Cmax)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
Time to maximum concentration (Tmax)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
Area under the concentration-time curve from time zero to time(AUC0-t)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
Area under the concentration-time curve extrapolated to infinity (AUC0-∞.)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
Elimination half-life (t1/2)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
Clearance (CL)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
Volume of distribution (Vz)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
Trough concentration (Cmin)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
Accumulatio of ratio (Rac)
Time Frame: approximately 1 year
|
approximately 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immunogenicity of SHR-1316
Time Frame: approximately 1 year
|
Anti-SHR-1316 antibody (ADA), neutralizing antibody (Nab)
|
approximately 1 year
|
|
Objective response rate (ORR)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
|
Progression-free survival (PFS)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
|
Duration of response (DoR)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
|
Disease control rate (DCR)
Time Frame: approximately 1 year
|
approximately 1 year
|
|
|
Overall survival (OS)
Time Frame: approximately 1 year
|
approximately 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SHR-1316-I-103
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.